Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C540S576000

Reexamination Certificate

active

07399758

ABSTRACT:
The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

REFERENCES:
patent: 2006/0046983 (2006-03-01), Hudyma et al.
patent: WO 2005/080399 (2005-09-01), None
patent: WO 2006/046030 (2006-05-01), None
patent: WO 2006/046039 (2006-05-01), None

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2741856

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.